May 14, 2019 10:12 JST

Source: NEC Corporation

NEC Becomes the First Japanese Company to Join the TESLA Consortium's Fight Against Cancer

TOKYO, May 14, 2019 - (JCN Newswire) - NEC Corporation (TSE: 6701) has become the first Japanese company to join the Tumor neoantigEn SeLection Alliance (TESLA) founded and managed by the Parker Institute for Cancer Immunotherapy and the Cancer Research Institute (CRI). This global bioinformatics collaborative includes scientists from more than 35 of the leading neoantigen research groups in academia, nonprofit and industry. The goal is to find the best algorithms to predict which cancer neoantigens encoded in DNA and RNA can be recognized by and stimulate an immune response.

Individualized neoantigen vaccines, which are tailored to each patient's tumor, are one of most advanced cancer treatments to show great promise for activating the immune system to fight cancer whilst reducing the chances of autoimmune responses.

NEC was accepted into the TESLA consortium given the uniqueness of the company's Neoantigen Prediction System. The prediction system utilizes NEC's cutting-edge AI technology, "NEC the WISE"(1), to identify and prioritize patient-specific neoantigens. NEC comprehensively evaluates candidate neoantigens with a primary focus placed on its in-house MHC-binding affinity prediction. These allow NEC to effectively prioritize the numerous candidate neoantigens identified in a single patient.

"By participating in this consortium, NEC will be able to collaborate with the world's leading research organizations and potentially improve the chances of survival for cancer patients with this new treatment option," said Osamu Fujikawa, Senior Vice President, NEC Corporation. "NEC focuses on the provision of social solutions and continues efforts to strengthen its next-generation healthtech businesses," he added.

(1) NEC the WISE
NEC the WISE is a term for the Company's cutting-edge portfolio of AI technologies.

Contact:
NEC
Seiichiro Toda        
s-toda@cj.jp.nec.com
+81-3-3798-6511
Source: NEC Corporation
Sectors: Cloud & Enterprise, BioTech

Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


DOCOMO, NTT, NEC and Fujitsu Develop Top-level Sub-terahertz 6G Device Capable of Ultra-high-speed 100 Gbps Transmission
April 11 2024 14:10 JST
 
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
April 10 2024 12:36 JST
 
NEC white paper proposes comprehensive process workflow for the application of AI-driven personalized cancer vaccines
April 08 2024 12:45 JST
 
NEC develops marketing strategy planning & effectiveness simulation technology using generative AI
March 25 2024 09:08 JST
 
NEC and NTT successfully conduct first-of-its-kind long-distance transmission experiment over 7,000km using 12-core optical fiber
March 22 2024 07:38 JST
 
NEC and Tokyo Medical and Dental University use AI to assist self-care for chronic lower back pain
March 21 2024 09:02 JST
 
NEC and Skyloom to Pioneer 100 Gbps Space Optical Communications, Transforming Global Internet Connectivity
March 20 2024 14:30 JST
 
NEC named to list of Top 100 Global Innovators by Clarivate for 13th consecutive year
March 07 2024 10:24 JST
 
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
March 05 2024 08:05 JST
 
Cisco, NEC and TIM Brazil improve TIM Brazil network quality with automation and advanced data analytics to enhance business customers experience
March 01 2024 21:00 JST
 
More Press release >>

Latest Press Release


More Latest Release >>